Anika Therapeutics, Inc.ANIKNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-1.4%
5Y CAGR-4.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-1.4%/yr
vs +10.5%/yr prior
5Y CAGR
-4.0%/yr
Consistent
Acceleration
-11.9pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$49.09M-11.6%
2024$55.55M-7.3%
2023$59.92M+17.0%
2022$51.23M-30.9%
2021$74.10M+23.4%
2020$60.06M+71.9%
2019$34.95M+1.8%
2018$34.34M+59.4%
2017$21.54M+19.6%
2016$18.01M-